RecruitingNCT06380686
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based Biomarkers, Treatment and Outcome
Head and Neck Carcinoma Clinical Research Platform for Molecular and Blood-based
Sponsor
AIO-Studien-gGmbH
Enrollment
120 participants
Start Date
Nov 7, 2024
Study Type
OBSERVATIONAL
Conditions
Summary
Prospective, open, non-interventional, multi-center clinical registry study with the aim to establish a comprehensive research platform reflecting the real-world treatment landscape for recurrent/metastatic head and neck tumor patients.
Eligibility
Min Age: 18 Years
Inclusion Criteria5
- Age ≥ 18 years
- Able to understand and willing to sign written informed consent
- Histologically or cytologically confirmed squamous cell carcinoma of the head and neck (oral cavity, oropharynx, hypopharynx or larynx)
- Patients not amenable for curative treatment who receive palliative systemic treatment or best supportive care
- Informed consent no later than four weeks after start of first-line palliative systemic treatment. For patients receiving "best supportive care only": no later than six weeks after diagnosis/recurrence or metastatic disease
Interventions
OTHERdata collection
Demography, Social history, Riskfactors, Relevant medical history, Oncological family history, Disease \& treatment history, Molecular Pathology and Results, Treatment data, Response data, progession free survial, overall survival.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06380686
Related Trials
Immune Biomarker Study for Cisplatin-ineligible Patients Receiving Chemoradiotherapy With Docetaxel
NCT069476681 location
De-Intensification of Postoperative Radiotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
NCT060304401 location
HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma
NCT059622425 locations
A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan (CuSToMIze)
NCT058940831 location
Trial of Stereotactic HYpofractionateD RadioAblative (HYDRA) Treatment of Laryngeal Cancer
NCT031144621 location